Jasper Ridge Partners’s Oric Pharmaceuticals ORIC Stock Holding History

Jasper Ridge Partners’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$226K	Hold	20,870	–	–	﹤0.01%	130
2026 Q1	$264K	Hold	20,870	–	–	0.01%	121
2025 Q4	$171K	Hold	20,870	–	–	﹤0.01%	128
2025 Q3	$250K	Hold	20,870	–	–	0.01%	127
2025 Q2	$212K	Hold	20,870	–	–	0.01%	133
2025 Q1	$116K	Hold	20,870	–	–	﹤0.01%	136
2024 Q4	$168K	Hold	20,870	–	–	0.01%	132
2024 Q3	$214K	Hold	20,870	–	–	0.01%	129
2024 Q2	$148K	Hold	20,870	–	–	﹤0.01%	134
2024 Q1	$287K	Hold	20,870	–	–	0.01%	120
2023 Q4	$192K	Hold	20,870	–	–	0.01%	133
2023 Q3	$126K	Hold	20,870	–	–	0.01%	130
2023 Q2	$162K	Hold	20,870	–	–	0.01%	129
2023 Q1	$119K	Hold	20,870	–	–	0.01%	141
2022 Q4	$123K	Hold	20,870	–	–	0.01%	138
2022 Q3	$67K	Hold	20,870	–	–	﹤0.01%	146
2022 Q2	$93K	Hold	20,870	–	–	0.01%	140
2022 Q1	$111K	Hold	20,870	–	–	0.01%	146
2021 Q4	$307K	Buy	+20,870	New	+$325K	0.01%	135

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jasper Ridge Partners's ORIC Position: Q2 2026 in Review

Jasper Ridge Partners held its Oric Pharmaceuticals (ORIC) position steady in Q2 2026 at 20,870 shares worth $226K. The position accounts for ﹤0.01% of the portfolio, ranked #130.

Jasper Ridge Partners first reported a position in ORIC in Q4 2021 and has held it in 19 quarters since. The position peaked at $307K in Q4 2021. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

Jasper Ridge Partners held 20,870 shares of Oric Pharmaceuticals worth $226K as of Q2 2026.
Jasper Ridge Partners left its Oric Pharmaceuticals share count unchanged in Q2 2026.
Oric Pharmaceuticals made up ﹤0.01% of Jasper Ridge Partners's portfolio in Q2 2026, its #130 holding.
Jasper Ridge Partners first reported a position in Oric Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
Jasper Ridge Partners's Oric Pharmaceuticals position peaked at $307K in Q4 2021.
180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Jasper Ridge Partners's 13F filing for Q2 2026, filed 13 Aug 2026.